Abstract
The use of interferon beta (IFNβ) in the treatment of multiple sclerosis (MS) has not changed greatly since its introduction. However, two new treatment paradigms have recently emerged—initiation of treatment as early in the course of the disease as possible and the use of higher doses with greater frequency to gain maximum therapeutic effect. The rationale for early treatment comes from evidence showing that early and irreversible pathology exists in very early stages of relapsing remitting MS (RRMS) often before significant disability is apparent and continues during remission. In addition, irreversible axonal damage begins early in the course of MS. Two relatively short-term studies indicate that it is possible to delay the onset of MS by early treatment with low-dose IFNβ-1a. The BENEFIT (BEtaferon®/Betaseron® in Newly Emerging MS For Initial Treatment) study is being undertaken to investigate whether early intervention with a high-dose and more frequent administration of IFNβ-1b (250 µg [8 MIU] every other day [eod]) has the ability to affect long-term clinical and magnetic resonance imaging (MRI) outcomes even more favourably. In addition, together with its follow-up study, BENEFIT will address the open question of long-term effects of early treatment on disease progression.
Results from the pivotal IFNβ-1b study, together with data from PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) showed the presence of a dose-response relationship for IFNβ in the treatment of RRMS. This finding was confirmed by the results of INCOMIN (INdependent COMparison of INterferons) and EVIDENCE (EVidence of Interferon Dose-response: European North American Comparative Efficacy), direct comparative studies of high-dose (250 µg IFNβ-1b, 44 µg IFNβ-1a), high-frequency versus lower dose (30 µg IFNβ-1a) and less frequent IFNβ regimens. Results from a pilot study in patients with RRMS have indicated that increasing the dose of IFNβ-1b to 500 µg (16 MIU) had a more pronounced biological effect compared with the standard 250 µg dose. The BEYOND (Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose) study is being undertaken to investigate whether IFNβ-1b 500 µg eod is superior to the standard 250 µg eod dose in treatment-naïve patients with RRMS. A third treatment arm will provide a comparison with glatiramer acetate 20mg subcutaneously once daily.
Similar content being viewed by others
References
Berger T, Rubner P, Schautzer F, Egg R, Ulmer H, Mayringer I, Dilitz E, Deisenhammer F, Reindl M (2003) Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med 349:139–145
Bjartmar C, Trapp BD (2001) Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences. Curr Opin Neurol 14:271–278
Bjartmar C, Kidd G,Mork S, Rudick R, Trapp BD (2000) Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients. Ann Neurol 48:893–901
Brex PA, Ciccarelli O, O’Riordan JI, Sailer M, Thompson AJ, Miller DH (2002) A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 346:158–164
Clanet M, Radue EW, Kappos L, Hartung HP, Hohlfeld R, Sandberg-Wollheim M, Kooijmans-Coutinho MF, Tsao EC, Sandrock AW (2002) A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS. Neurology 59:1507–1517
Comi G, Filippi M, Barkhof F, Durelli L, Edan G, Fernandez O, Hartung H, Seeldrayers P, Sorensen PS, Rovaris M, Martinelli V, Hommes OR (2001) Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 357:1576–1582
De Stefano N, Narayanan S, Francis GS, Arnaoutelis R, Tartaglia MC, Antel JP, Matthews PM, Arnold DL (2001) Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol 58:65–70
Durelli L, Verdun E, Barbero P, Bergui M, Versino E, Ghezzi A, Montanari E, Zaffaroni M (2002) Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 359:1453–1460
Goodin DS, Frohman EM, Garmany GP Jr, Halper J, Likosky WH, Lublin FD, Silberberg DH, Stuart WH, van den Noort S (2002) Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 58:169–178
IFNB Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43:655–661
IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group (1995) Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 45:1277–1285
Jacobs LD, Cookfair DL, Rudick RA, Herndon, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Granger CV, Simon JH, Alam JJ, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer EF 3rd, Priore RL, Pullicino PM, Scherokman BJ, Whitham RH, et al. (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 39:285–294
Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ, Simonian NA, Slasor PJ, Sandrock AW (2000) Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 343:898–904
Knobler RL, Greenstein JI, Johnson KP, Lublin FD, Panitch HS, Conway K, Grant-Gorsen SV, Muldoon J, Marcus SG, Wallenberg JC, et al. (1993) Systemic recombinant human interferonbeta treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up. J Interferon Res 13:333–340
Kuhlmann T, Lingfield G, Bitsch A, Schuchardt J, Brück W (2002) Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain 125:2202–2212
McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, van den NS, Weinshenker BY, Wolinsky JS (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50:121–127
Narayanan S, De Stefano N, Francis GS, Arnaoutelis R, Caramanos Z, Collins DL, Pelletier D, Arnason BGW, Antel JP, Arnold DL (2001) Axonal metabolic recovery in multiple sclerosis patients treated with interferon beta-1b. J Neurol 248:979–986
Panitch H, Goodin DS, Francis G, Chang P, Coyle PK, O’Connor P, Monaghan E, Li D, Weinshenker B (2002) Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial. Neurology 59:1496–1506
Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, Johnson KP, Sibley WA, Silberberg DH, Tourtellotte WW (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13:227–231
PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group (1998) Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 352:1498–1504
The PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group, and the University of British Columbia MS/MRI Analysis Group (2001) PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 56:1628–1636
Rothuizen LE, Buclin T, Spertini F, Trinchard I, Munafo A, Buchwalder PA, Ythier A, Biollaz J (1999) Influence of interferon beta-1a dose frequency on PBMC cytokine secretion and biological effect markers. J Neuroimmunol 99:131–141
Simon JH, Jacobs LD, Campion MK, Rudick RA, Cookfair DL, Herndon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Simonian N, Lajaunie M, Miller DE, Wende K, Martens-Davidson A, Kinkel RP, Munschauer FE III., Brownscheidle CM (1999) A longitudinal study of brain atrophy in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology 53:139–148
Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L (1998) Axonal transection in the lesions of multiple sclerosis. N Engl J Med 338:278–285
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hartung, HP. Early treatment and dose optimisation. J Neurol 252 (Suppl 3), iii44–iii50 (2005). https://doi.org/10.1007/s00415-005-2017-z
Issue Date:
DOI: https://doi.org/10.1007/s00415-005-2017-z